



PTO/SB/08B (02-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Applicati n Number	10/090,238
		Filing Date	March, 2, 2002
		First Named Inventor	Rong XIANG, et al.
		Art Unit	1632
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	TSRI-830.0

RECEIVED

APR 30 2003

TECH CENTER 1600/2900

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Bor		Rong XIANG, et al., CLINICAL CANCER RESEARCH, Vol. 7, pp. 856s-864s (March 2001) (Suppl.).	
		James W. HODGE, et al., CANCER RESEARCH, Vol. 59, pp. 5800-5807 (November 15, 1999).	
		Erik KASS, et al., CANCER RESEARCH, Vol. 59, pp. 676-683 (February 1, 1999).	
		Stephen D. GILLIES, et al., JOURNAL OF IMMUNOLOGY, pp. 6195-6203 (1998).	
		Joanne P. McLAUGHLIN, et al., CANCER RESEARCH, Vol. 56, pp. 2361-2367 (May 15, 1996).	
		Shin SASAKI, et al., NATURE BIOTECHNOLOGY, Vol. 19, pp. 543-547 (June 2001).	
		Nicholas P. RESTIFO, NATURE BIOTECHNOLOGY, Vol. 19, pp. 527-528 (June 2001).	
		Wolfgang W. LEITNER, et al., CANCER RESEARCH, Vol. 60, pp. 51-55 (January 1, 2000).	
		N.P. RESTIFO, et al., GENE THERAPY, Vol. 7, pp. 89-92, (2000).	
		Andreas G. NIETHAMMER, et al., NATURE MEDICINE, Vol. 8 (12), pp. 1369-1375 (December, 2002).	

Examiner Signature	<i>Macquart</i>	Date Considered	09/23/2004
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.